ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. CEO Ameet Mallik will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 2:00 p.m. ET.

The presentation will be accessible through a live webcast on the Events & Presentations page of ADC Therapeutics' investor relations website section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available for approximately 30 days following the event.

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET.

A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit the Company website at adctherapeutics.com and follow us on LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-the-guggenheim-smid-cap-biotech-conference-302363877.html

SOURCE ADC Therapeutics SA

FAQ

When is ADC Therapeutics (ADCT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

ADC Therapeutics will present at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET.

How can investors watch ADC Therapeutics' presentation at the Guggenheim Conference?

Investors can watch the presentation through a live webcast available on the Events & Presentations page in the IR section of ADC Therapeutics' website.

How long will the replay of ADCT's Guggenheim Conference presentation be available?

The webcast replay will be available for approximately 30 days following the presentation.

Who will represent ADC Therapeutics at the Guggenheim SMID Cap Biotech Conference 2025?

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, will represent the company in a fireside chat at the conference.